NRSNW (NRSNW) Stock Price & Analysis
NRSNW (NRSNW) rose 0.00% to USD 0.19 as of June 10, 2026 at 14:19 UTC, according to Nexqual real-time market data.
NRSNW last closed at USD 0.19; the session ranged USD 0.15–0.19 on volume of 256 shares. Market capitalization is —, with a 52-week range of USD 0.15–0.19 (NCM). Source: Nexqual, June 10, 2026 at 14:19 UTC.
Key Statistics (as of June 10, 2026 at 14:19 UTC)
| Price | USD 0.19 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.19 |
| Open | USD 0.3 |
| Day Range | USD 0.15 – 0.19 |
| 52-Week Range | USD 0.15 – 0.19 |
| Volume | 256 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (NRSNW)
Nexqual's technical model rates NRSNW "BUY" based on 5 bullish and 1 bearish signals across 66 daily candles, as of June 10, 2026 at 14:19 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0.21) |
| MACD | 0 (negative) |
Analyst Ratings (NRSNW)
Wall Street analysts rate NRSNW "None", per Nexqual as of June 10, 2026 at 14:19 UTC.
| Consensus Rating | None |
|---|
Earnings (NRSNW)
Source: Nexqual, June 10, 2026 at 14:19 UTC.
Financials & Fundamentals (NRSNW)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -2174.98% |
| Current Ratio | 0.31 |
| Total Cash | $166,000 |
| Total Debt | $170,000 |
| Free Cash Flow | $-3.87M |
Source: Nexqual, June 10, 2026 at 14:19 UTC.
Financial Health Score (NRSNW)
Nexqual rates NRSNW's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 14:19 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $166K cash, no debt |
| Cash Flow | Weak — Operating cash flow -$8M |
| Efficiency | Critical — ROE -2175%, ROA -247.3% |
Ownership (NRSNW)
| Float | 24.95M |
|---|
Source: Nexqual, June 10, 2026 at 14:19 UTC.
Leadership (NRSNW)
NRSNW is led by Alon Ben-Noon (age 46), Co-Founder, CEO & Director, per Nexqual as of June 10, 2026 at 14:19 UTC.
| Co-Founder, CEO & Director | Alon Ben-Noon (age 46) |
|---|---|
| Chief Financial Officer | Or Eisenberg (age 44) |
| Chief Technology Officer | Niva Russek-Blum (age 46) |
Major Backers & Investors (NRSNW)
Notable institutional backers of NRSNW include Empery Asset Management, LP, Clear Street Group Inc., according to Nexqual as of June 10, 2026 at 14:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Empery Asset Management, LP | 7.41% |
| Clear Street Group Inc. | 4.68% |
Source: Nexqual, June 10, 2026 at 14:19 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NRSN | NeuroSense Therapeutics Ltd. | USD 0.79 | ▲ 5.05% |
| NTRBW | Nutriband Inc. Warrant | USD 0.9 | ▲ 0% |
| NLSPW | NLS Pharmaceutics Ltd. | USD 0.02 | ▲ 0% |
| REVBW | Revelation Biosciences, Inc. | USD 0.01 | ▲ 24.18% |
| KTTAW | Pasithea Therapeutics Corp. Warrant | USD 0.01 | ▼ 39.45% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 14:19 UTC. This page is informational and not investment advice.